Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
4.01 USD | -0.99% | -4.07% | -83.86% |
14.05. | RAPT THERAPEUTICS, INC. : Vom Kauf zur neutralen Bewertung von Wolfe Research | ZM |
10.05. | RAPT THERAPEUTICS, INC. : Guggenheim gibt eine neutrale Bewertung ab | ZM |
Kurzporträt
Mitarbeiterzahl: 126
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Brian Wong
CEO | Chief Executive Officer | 52 | 01.08.15 |
Rodney Young
DFI | Director of Finance/CFO | 61 | 02.12.19 |
Jim Farmer
CTO | Chief Tech/Sci/R&D Officer | - | 04.05.22 |
William Ho
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.05.15 |
Dirk Brockstedt
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.01.18 |
Nipun Davar
CTO | Chief Tech/Sci/R&D Officer | - | 13.02. |
Investor Relations Contact | 63 | - | |
General Counsel | - | 03.05.23 | |
Adnan Rahman
PRN | Corporate Officer/Principal | - | 28.09.22 |
Shari L. Geffon
PRN | Corporate Officer/Principal | - | 04.05.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Mary Gray
BRD | Director/Board Member | 71 | 04.12.19 |
William Rieflin
CHM | Chairman | 64 | 01.05.15 |
Wendye Robbins
BRD | Director/Board Member | 63 | 22.10.19 |
Brian Wong
CEO | Chief Executive Officer | 52 | 01.08.15 |
Michael Giordano
BRD | Director/Board Member | 66 | 01.01.18 |
Linda Kozick
BRD | Director/Board Member | 66 | 01.12.16 |
Director/Board Member | 46 | 09.11.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 34 799 702 | 32 933 918 ( 94,64 %) | 0 | 94,64 % |
Unternehmenskontakt
Sektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-83.86% | 140 Mio. | |
+11.60% | 106 Mrd. | |
-4.68% | 24.28 Mrd. | |
-0.82% | 21.96 Mrd. | |
-10.12% | 18.16 Mrd. | |
-42.12% | 16.37 Mrd. | |
-17.47% | 15.56 Mrd. | |
+2.77% | 13.63 Mrd. | |
+34.58% | 12.27 Mrd. | |
+77.64% | 8.87 Mrd. |
- Börse
- Aktien
- A2PNYQ Aktie
- Unternehmen RAPT Therapeutics, Inc.